RecruitingNCT06528418

Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

Sponsor

ChromX Health

Enrollment

10,000 participants

Start Date

Jun 30, 2024

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Lung Infection COPD Bronchial Asthma Pulmonary Embolism Interstitial Lung Disease Pulmonary Fibrosis Bronchiectasis Bronchitis Pulmonary Arterial Hypertension Pulmonary Tuberculosis Pulmonary Abscess Emphysema Lung Injury Cystic Fibrosis of the Lung Preserved Ratio Impaired Spirometry

Summary

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases. 2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria4

Males or females, age must be 18 years old or above.
Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data.
Patients must have a clear clinical diagnosis.
All participants must sign a written informed consent form.

Exclusion Criteria6

Pregnant women.
Individuals with a history of cancer other than lung disease.
Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants.
Individuals with other severe organic diseases or mental illnesses.
Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc.
Any other condition that researchers deem unsuitable for participation in this clinical trial.

Interventions

OTHERGas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system

Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID

Locations(1)

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06528418

Related Trials

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828763 locations

Study of Novel Treatment Combinations in Patients With Lung Cancer

NCT05633667100 locations